Clinical trials: Type2 Diabetes
- Condition Type2 Diabetes
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Diabetes, Diabetes Mellitus, Type 2
Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects
This trial is conducted in Europe. The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) of single doses of NNC0113-0987 in healthy male subjects.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01690169
- Testing
- NNC0113-0987
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type II Diabetes
A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects
The trial is to assess the bioequivalence between HR20033 FDC tablet and co-administration of SHR3824 tablets and metformin XR tablets.
- Trial name
- NCT05108350
- Testing
- T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR, T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Type 2 Diabetes Mellitus
Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)
To demonstrate bioequivalence of a 2.5 mg saxagliptin/500 mg metformin (glucophage) immediate release (IR) fixed dose combination (FDC) tablet to the 2.5 mg saxagliptin tablet and 500 mg metformin IR tablet co-administered to…
- Trial name
- NCT00899470
- Testing
- Co-administration of Saxagliptin and Metformin IR, Fasted, Saxagliptin/Metformin, Fasting, Co-administration of Saxagliptin and Metformin IR, Fed
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Essential Hypertension, Type 2 Diabetes
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-3" and "BR1019-2" in healthy volunteers
- Trial name
- NCT06636877
- Testing
- BR1019, BR1019-2, BR1019-3
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Prediabetic State, Diabetes Mellitus, Type 2
Noninvasive Skin Spectroscopy for Diabetes Screening
The objective of this study is to assess the performance of a noninvasive device for the early screening of Diabetes Mellitus.
- Trial name
- NCT00358254
- Where
- 2 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- InLight Solutions
Type 2 Diabetes Mellitus
Study on Drug Interaction of HRS-1780 Tablets, Henagliflozin Tablets, Metformin Tablets and HRS-7535 Tablets in Healthy Human
This study was designed as a single-center, single-arm, open, fixed-sequence, self-controlled trial in healthy subjects.
- Trial name
- NCT06495931
- Testing
- HRS-1780 tablets, HR20033 tablets, HRS-7535 tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Type 2 Diabetes Mellitus
Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)
The purpose of this study is to test the safety and effectiveness of sitagliptin in patients with type 2 diabetes.
- Trial name
- NCT00541775
- Testing
- Sitagliptin, Comparator: Rosiglitazone, Comparator: Metformin
- Volunteers
- 273 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fed Conditions
The purpose of this clinical study is to evaluate the pharmacokinetics and safety between single oral administration of BR3006 and co-administration of BR3006A, BR3006B and BR3006C in healthy adult volunteers under fed conditions
- Trial name
- NCT06890299
- Testing
- BR3006, BR3006A, BR3006B
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type 2 Diabetes
The Pharmacokinetics Study of Single and Multiple Dose of SP2086 in Healthy Volunteers
SP2086 is a novel inhibitor of Dipeptide base peptidase 4, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia.
- Trial name
- NCT02826044
- Testing
- SP2086
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy Volunteers, Type 2 Diabetes
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets
In this study two different tablets for oral use of a known investigational medicinal product, called semaglutide, will be tested.
- Trial name
- NCT04109508
- Testing
- Oral semaglutide
- Where
- Germany
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type2 Diabetes
Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults
A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin 5 mg and Empagliflozin 25 mg or Dapagliflozin 10 mg after Oral Administration in…
- Trial name
- NCT03766724
- Testing
- Evogliptin→Evogliptin+Empagliflozin→Empagliflozin, Empagliflozin→Evogliptin→Evogliptin+Empagliflozin, Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin
- Where
- South Korea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Type 2 Diabetes
Bias Source of Signal in SCOUT DS
The primary objective is to identify device characteristics, components or subsystems that manifest as screening score bias in SCOUT DS.
- Trial name
- BSOS (NCT01550328)
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- VeraLight, Inc.
Type 2 Diabetes Mellitus
Bioavailability and Food Effects of HRS-7535 Tablets With Different Formulating Processes in Healthy Subjects
This study was designed as a a single-center, randomized, open, interleaved (3-cycle, 3-sequence) trial. It is planned to enroll 18 healthy subjects.
- Trial name
- NCT06422039
- Testing
- HRS-7535(D) Tablets, HRS-7535(C) Tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Diabetes type2
A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of D745, D759, and D150
A clinical trial to compare the pharmacokinetic characteristics and safety among D745, D759, and D150 in healthy subjects
- Trial name
- NCT05928637
- Testing
- D745, D759, D150
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715
10 healthy volunteers will be enrolled to each receive two subcutaneous injections of ISIS 113715 in the abdomen on Study Day 1. Each subject will receive their two injections within a 5-minute period.
- Trial name
- NCT00365781
- Testing
- ISIS 113715
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Bioequivalence, Diabetes Mellitus, Type 2
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.
The objective of this study was to evaluate and compare the bioavailability and therefore to assess the bioequivalence of two different formulations of sitagliptin/metformin extended release tablets after a single oral dose…
- Trial name
- NCT06124573
- Testing
- Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
- Where
- Mexico
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Galenicum Health
Diabetes Mellitus, Type 2, Diabetic Foot
Non-invasive Imaging for In-vivo Quantification of Skin Composition and Structure
The goal of this clinical investigation is to explore a non-invasive technology for measuring the microcirculatory structure, composition and function in patients from a primary care population. The main aims are: 1.
- Conditions
- Diabetes Mellitus, Type 2, Diabetic Foot, Peripheral Arterial Disease, Skin Cancer
- Trial name
- Spectrum1 (NCT06976073)
- Where
- 3 sites in Sweden
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- HJN Sverige AB/Neko Health
Type 2 Diabetes Mellitus
Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-370 and D745 in Healthy Adults
A randomized, open-label, single dose, two-way crossover study to compare the pharmacokinetics and safety/tolerability of CKD-370 with D745 in healthy volunteers
- Trial name
- NCT03849495
- Testing
- CKD-370, D745
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus
A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403
This is a Phase 1, multicenter, open label, single dose study. A total of 30 subjects are planned (5 groups of 6 subjects each.)
- Trial name
- NCT01131091
- Testing
- SK-0403
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Kowa Research Institute, Inc.
Diabetes Mellitus, Type II
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers
This study is a randomized, open-label, single dose, 2-way crossover study to compare the pharmacokinetic characteristics of CKD-395 0.5/1000 mg in healthy male volunteers.
- Trial name
- NCT02565368
- Testing
- Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg, CKD-395 0.5/1000mg
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical